Bellerophon Therapeutics (BLPH) Upgraded to “Buy” by Zacks Investment Research - Fairfield Current
Bellerophon Therapeutics (BLPH) Upgraded to “Buy” by Zacks Investment Research Fairfield Current
Bellerophon Therapeutics (NASDAQ:BLPH) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research note issued on ...
Comments
Post a Comment